StockData
Theriva Biologics, Inc. logo

Theriva Biologics, Inc. (TOVX) stock

TOVXNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 4/30
$0.14+0.00 (0.00%)

Close on Nov 17, 2026Market cap $6.42MP/E –Yield –

Theriva Biologics total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

Theriva Biologics's total debt was $63.00K at Dec 31, 2023. For fiscal 2023 it was $63.00K, up 10.5% from the year before.

Annual total debt

PeriodPeriod endValueChange
FY2023Dec 31, 2023$63.00K+10.5%
FY2022Dec 31, 2022$57.00K–

Quarterly total debt

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2023Dec 31, 2023$63.00K+10.5%
Q3 FY2023Sep 30, 2023$65.00K+25.0%
Q2 FY2023Jun 30, 2023$67.00K+19.6%
Q1 FY2023Mar 31, 2023$66.00K-2.9%
Q4 FY2022Dec 31, 2022$57.00K–
Q3 FY2022Sep 30, 2022$52.00K–
Q2 FY2022Jun 30, 2022$56.00K–
Q1 FY2022Mar 31, 2022$68.00K–

More Theriva Biologics figures

See a number that looks wrong?